Ani pharmaceuticals announces refiling of cortrophin snda with fda

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq: anip) today announced that the company has re-filed its supplemental new drug application (“snda”) for cortrophin® gel with the u.s. food and drug administration (“fda”). “we are delighted to have re-filed our snda for cortrophin gel in the last week of june. ani has carefully reviewed every communication from the fda with our internal subject matter experts and enlisted additional expert advice from i
ANIP Ratings Summary
ANIP Quant Ranking